Mobile-health Network Solutions Announces Effective Date of Reverse Stock Split
Singapore, Singapore--(Newsfile Corp. - June 25, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI-powered digital health platform, today announced a one-for-six reverse stock split (the "Reverse Stock Split") of the Company's Class A Ordinary Shares ("Class A Ordinary Shares") will become effective at 12:01 a.m. Eastern Time on Monday, June 29, 2026. The Class A Ordinary Shares will continue to trade under its ex
2026-06-25 9:00 AM EDT | Mobile-health Network Solutions
AAMI Returns to Costa Rica with Advanced QMSR Course for Medical Device Professionals
Arlington, Virginia--(Newsfile Corp. - June 25, 2026) - Building on a partnership launched five years ago to strengthen the region's world-class medical device sector, the Association for the Advancement of Medical Instrumentation (AAMI) is returning to Costa Rica this August with a three-day course on FDA's Quality Management System Regulation. "Design and Development - Navigating and Implementing QMSR" will be held from August 25-27, 2026, offering medical device industry professional
2026-06-25 8:50 AM EDT | Association for the Advancement of Medical Instrumentation
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Syner-G BioPharma Group ("Syner-G") to oversee GMP manufacturing of BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is active against neuroreceptors involved in
2026-06-25 8:00 AM EDT | BetterLife Pharma Inc.
QScreen AI Announces Close of First Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, is pleased to announce the closing of the first tranche of its previously announced non-brokered private placement. The Company is pleased to announce that it has completed the first tranche of its previously announced non-brokered private pla
2026-06-25 7:01 AM EDT | QScreen AI Inc.
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining the
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-25 7:00 AM EDT | Phio Pharmaceuticals Corp.
Custom Health Announces Strategic Leadership Appointments to Support Continued Growth and Regulatory Excellence
Robert Guzman has been appointed Chief Compliance & Regulatory Officer, bringing extensive experience in regulatory oversight, compliance management, and quality assurance to strengthen Custom Health's governance framework and support the Company's continued expansion across highly regulated healthcare and pharmacy markets. Brent Herman, Founder, President and Chief Executive Officer of InnovativeRx US Holdings, Inc., has been appointed Executive Vice President, Cor
Technologies, Pharmaceutique, Santé
2026-06-25 6:30 AM EDT | Custom Health Holdings Inc.
Dr. Christina Rahm and DRC Ventures Accept Prestigious Gold Stevie(R) Award for Patent-Driven Manufacturing Innovation
New York, New York--(Newsfile Corp. - June 24, 2026) - Dr. Christina Rahm, founder and CEO of DRC Ventures, was honored with a Gold Stevie® Award at the 2026 American Business Awards® ceremony in New York City for her groundbreaking work in developing the patent-driven manufacturing infrastructure
Biotechnologies, Aliments / boissons, Santé
2026-06-24 1:20 PM EDT | DRC Ventures
CORRECTION FROM SOURCE: Mobile-health Network Solutions Expands into Cybersecurity with Skylink-Contfinity Partnership, Launching OtterSG Bundled Solution for Clinics in Singapore
Singapore, Singapore--(Newsfile Corp. - June 24, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MHNS"), a leading AI-powered digital health platform headquartered in Singapore, today announced that its subsidiary Skylink Innovations Pte. Ltd. has entered into a Strategic Partnership Agreement with Contfinity Pte. Ltd. to deliver a bundled offering of the OtterSG Clinic Management System (CMS) and managed cybersecurity services to healthcare provide
2026-06-24 11:28 AM EDT | Mobile-health Network Solutions
Edison Issues Report on Alter Ego Media (AEM)
London, United Kingdom--(Newsfile Corp. - June 24, 2026) - Edison issues report on Alter Ego Media (ATH: AEM). Alter Ego Media (AEM) owns a portfolio of leading media and entertainment assets in Greece. Management's strategy is to evolve the group from a traditional advertising-dependent media company into a broader media and entertainment business with more diverse and resilient revenue streams, while delivering operational efficiencies. The relatively underdeveloped nature of the Gree
Services bancaires / financiers, Matériel informatique, Logiciels, Santé
2026-06-24 9:30 AM EDT | Edison Group
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - June 24, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-24 7:00 AM EDT | Phio Pharmaceuticals Corp.
Rise Nano Optics Announces Strategic Partnership with SportifEye Optics to Produce and Commercialize SpectraGuard(TM) Lenses in the United States
Vancouver, British Columbia--(Newsfile Corp. - June 24, 2026) - Rise Nano Optics Ltd. (CSE: EYE) ("Rise" or the "Company"), a health technology company advancing vision care through patented nanotechnology lens solutions, today announced a strategic partnership with SportifEye Optics ("SportifEye"), a cutting-edge, full-service optical laboratory and VSP®-Authorized Lab based in Southern California, to support the production and commercialization of its SpectraGuard
2026-06-24 12:15 AM EDT | Rise Nano Optics Ltd.
Mobile-health Network Solutions Expands into Cybersecurity with Skylink-Contfinity Partnership, Launching OttterSG Bundled Solution for Clinics in Singapore
Singapore, Singapore--(Newsfile Corp. - June 23, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MHNS"), a leading AI-powered digital health platform headquartered in Singapore, today announced that its subsidiary Skylink Innovations Pte. Ltd. has entered into a Strategic Partnership Agreement with Contfinity Pte. Ltd. to deliver a bundled offering of the OttterSG Clinic Management System (CMS) and managed cybersecurity services to healthcare provid
2026-06-23 4:30 PM EDT | Mobile-health Network Solutions
UberDoc Health Technologies Appoints Lemonaid Health Co-Founder Paul Johnson to Advisory Board and Changes Name to Apptly Health Technologies Corp.
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL0) (the "Company" or "Apptly"), operator of the UberDoc direct-pay healthcare marketplace, is pleased to announce the appointment of Paul Johnson to its advisory board (the "Advisory Board"). Johnson co-founded Lemonaid Health, the first national direct-to-consumer telehealth service in the United States, and led it as Chie
2026-06-23 8:30 AM EDT | Apptly Health Technologies Corp.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026
Northvale, New Jersey--(Newsfile Corp. - June 23, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it will release its 2026 year-end financial results on Monday, June 29, 2026. Elite's management will host a live conference call on Tuesday, June 30th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update. St
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-23 7:00 AM EDT | Elite Pharmaceuticals, Inc.
Therma Bright Announces Expanded U.S. Orders for Venowave and Mobilizes Supply Chain for Upcoming Sales Volume
Toronto, Ontario--(Newsfile Corp. - June 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, is pleased to announce continued sales momentum for its Venowave mobile compression device in the United States, highlighted by additional follow-on orders from Horizon Health USA ("Horizon") and from Gen-X Med. Building on the rapid deployment of previous ship
Technologies, Biotechnologies, Santé
2026-06-23 6:30 AM EDT | Therma Bright Inc.
Custom Health Holdings Inc. to Commence Trading on the Toronto Stock Exchange
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - Custom Health Holdings Inc. (TSX: CHLT) (formerly, Queue Ventures Ltd.) ("Custom Health" or the "Company"), further to its press release dated June 5, 2026, is pleased to announce that it has received final approval for listing on the Toronto Stock Exchange (the "TSX"). The common shares of the Company (CUSIP 23204J104 / ISIN CA23204J1049) ("Common Shares") will commence trading on the TSX un
Technologies, Pharmaceutique, Santé
2026-06-22 5:45 PM EDT | Custom Health Holdings Inc.
CBD of Denver Announces Updated Corporate Website Reflecting Strategic Pivot into Artificial Intelligence
Cape Town, South Africa--(Newsfile Corp. - June 22, 2026) - CBD of Denver, Inc. (OTCID: CBDD), a publicly traded company, is pleased to announce that it has launched an updated corporate website at www.cbdofdenver-inc.com. The new website reflects the Company's exciting strategic transformation and its forward-looking direction as it actively explores merger and acquisition opportunities within the artificial intelli
Cannabis, Santé, Extracteurs de cannabis, Producteurs de cannabis
2026-06-22 10:53 AM EDT | CBD of Denver Inc.
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") today announced it has closed a CAD $2,000,000 convertible debenture financing ("Debenture" or "Financing"). The Debenture will fund the remaining IND-enabling work on the Company's lead candidate, BETR-001, as BetterLife sharpens its focus on neurological pain indications, with an initial emphasis on cluster headache
2026-06-22 8:00 AM EDT | BetterLife Pharma Inc.
Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement
Houston, Texas--(Newsfile Corp. - June 22, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the beginning of a new commercial chapter for VitaCookies with the signing of its first licensing agreement. This milestone moves VitaCookies from internal development toward commercial execution, positioning the brand as a structured growth opportunity built on CBIH's formulations, operatio
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-06-22 7:00 AM EDT | Cannabis Bioscience International Holdings
Neural Therapeutics Inc. Announces Transition to Semi-Annual Financial Reporting
Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions provided under Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduced by the Canadian Securities Administrators ("CSA"), the pilot program under
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-06-19 12:16 PM EDT | Neural Therapeutics Inc.